A new report from Unit 42 details how cybercriminals can use large language models to create dynamic phishing attacks. The technique generates unique JavaScript for each victim, evading signature-based security tools.
Microsoft is announcing the Maia 200, its latest in-house AI accelerator. It claims significant performance advantages over chips from Amazon and Google and will be used to run OpenAI’s GPT-5.2.
AI assistants are getting a lot of buzz, but actual daily use in the workplace remains shockingly low. The jump from pilot programs to full-scale deployment is hitting major roadblocks around trust and security.
Xbox is trying to standardize day-one releases on PlayStation 5, but admits it’s been inconsistent. An executive says the delayed PS5 version of Forza Horizon 6 is due to development constraints, not a strategic holdback. The era of Xbox console exclusivity for its own sake is over.
The European Union has opened a formal investigation into X over the spread of illegal AI-generated images by Grok. This comes after X claimed to have implemented “technological measures” to curb the creation of sexualized images of real people.
The backlash against generative AI in creative fields is getting official. Both the Science Fiction and Fantasy Writers Association and San Diego Comic-Con have recently instituted hard bans. It’s a messy but decisive move.
A new report details the alarming rise of an AI crimeware economy. Low-cost “Dark LLM” subscriptions and deepfake kits are enabling fraud at a scale and sophistication that’s overwhelming traditional defenses.
According to Techmeme, Apple is preparing a major AI strategy reset, including a Gemini-powered Siri announcement next month and a reimagined chatbot-like Siri at WWDC. In a separate but telling report, Microsoft says it receives about 20 annual requests for BitLocker recovery keys and, in a Guam ca
The hype for AI-powered Copilot PCs is crashing into reality. Major PC makers like Dell are already backing off the “AI-first” message because, frankly, consumers just don’t get it.
A new CRISPR startup, Aurora Therapeutics, is betting that regulators will create a new pathway for personalized gene-editing drugs. Their plan is to get a single treatment approved that can be tweaked for different mutations without new trials.
